Elanco Animal Health (NYSE:ELAN) Releases FY 2026 Earnings Guidance

Key Points

• FY 2026 guidance: Elanco set EPS guidance of 1.030–1.090 and revenue guidance of $5.0–$5.1 billion, and updated Q2 2026 EPS guidance to 0.250–0.285 (FY EPS range matches the consensus 1.03).
• Quarterly beat: Elanco reported $0.40 EPS vs $0.34 expected and $1.37B revenue vs $1.28B expected, delivering 7.16% ROE despite a negative net margin of -4.92%.
• Analyst sentiment and stock snapshot: The consensus rating is "Moderate Buy" with a $27.90 target after several upward price-target revisions, and the shares trade near $23 with a roughly $11.5B market cap and a negative P/E.

Elanco Animal Health (NYSE:ELAN - Get Free Report) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.030-1.090 for the period, compared to the consensus estimate of 1.030. The company issued revenue guidance of $5.0 billion-$5.1 billion, compared to the consensus revenue estimate of $5.0 billion. Elanco Animal Health also updated its Q2 2026 guidance to 0.250-0.285 EPS.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ELAN shares. JPMorgan Chase & Co. lifted their price objective on Elanco Animal Health from $24.00 to $28.00 and gave the stock an "overweight" rating in a report on Thursday, February 19th. Wall Street Zen cut Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 18th. Leerink Partners lifted their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the stock an "outperform" rating in a report on Tuesday, February 24th. KeyCorp lifted their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. Finally, Weiss Ratings raised Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $27.90.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $23.05 on Wednesday. Elanco Animal Health has a 1 year low of $9.42 and a 1 year high of $27.72. The stock has a market cap of $11.46 billion, a PE ratio of -48.02, a P/E/G ratio of 2.87 and a beta of 1.69. The stock has a fifty day moving average price of $23.82 and a 200 day moving average price of $23.29. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.28 billion. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Sell-side analysts forecast that Elanco Animal Health will post 1.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors have recently made changes to their positions in the stock. Moors & Cabot Inc. acquired a new position in shares of Elanco Animal Health in the third quarter worth $206,000. Kotler Kevin acquired a new position in shares of Elanco Animal Health in the fourth quarter worth $205,000. Kestra Advisory Services LLC acquired a new position in shares of Elanco Animal Health in the fourth quarter worth $168,000. Empowered Funds LLC raised its holdings in shares of Elanco Animal Health by 35.2% in the first quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock worth $166,000 after acquiring an additional 4,121 shares during the last quarter. Finally, Cresset Asset Management LLC grew its position in shares of Elanco Animal Health by 12.8% in the second quarter. Cresset Asset Management LLC now owns 11,338 shares of the company's stock valued at $162,000 after purchasing an additional 1,287 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.